Stroke Management: From Syndrome to Mechanism and Deterioration

The Stroke note establishes the imaging background. I start here with the management problem: what syndrome has occurred, what mechanism could explain it, which process is still treatable, and what would explain subsequent worsening?

This is a reconstruction of a teaching deck, with source checks where its claims need qualification. It is study material, not clinical advice or a treatment protocol. Practice guidance changes. Numerical thresholds below belong to the named studies, classification systems, or the deck. They are not independent instructions for patient care. Where a figure is marked not traced to the primary source, I could reach the bibliographic record but not the full text, so the number stands as the deck’s and not as one I checked.

Management has several simultaneous objectives

The deck’s repeated management diagram separates treatment of the immediate lesion from preservation of physiological stability, recovery, and prevention of another event. These objectives overlap in time. The time sensitivity explains why the deck places the reperfusion decision before a complete etiologic classification.

Its treatment branches also explain why “a procedure was performed” does not establish that every subsequent problem has been addressed.

Problem	Treatment purpose in the deck’s framework
Acute arterial ischemia	Restore flow when the clinical situation meets the applicable reperfusion criteria.
Intracerebral hemorrhage	Limit further bleeding and address the hematoma, mass effect, or hydrocephalus in selected circumstances.
Aneurysmal subarachnoid hemorrhage	Secure the bleeding aneurysm through a surgical or endovascular approach and manage associated complications.
Deterioration from swelling	Support threatened brain function and consider decompression.
Continuing embolic or thrombotic risk	Identify the mechanism that informs secondary prevention.

Thrombectomy removes an arterial clot. Aneurysm coiling excludes an aneurysm from the circulation. Clipping, hematoma evacuation, decompressive surgery, and external ventricular drainage have different targets. Drainage addresses cerebrospinal fluid accumulation; it does not secure an aneurysm. Availability of an endovascular service therefore does not establish availability of the neurosurgical and critical care capabilities needed later.

The 2022 AHA/ASA intracerebral hemorrhage guideline and 2023 aneurysmal subarachnoid hemorrhage guideline provide separate management frameworks. I retain that separation rather than turning the deck’s hemorrhage branch into a universal surgical algorithm.

Localize the syndrome and preserve the examination

The useful question is how the deficits fit together. Weakness alone leaves many possibilities; its distribution and accompanying language, attention, visual, sensory, or cranial nerve findings make a syndrome more informative.

The following reconstructs the deck’s clinical patterns without repeating the vascular anatomy in the earlier note. These are localization clues, not a treatment eligibility table.

Clinical pattern	Localization suggested by the deck	Consequence for understanding care
Transient loss of vision in one eye	Retinal ischemia associated with the ipsilateral carotid circulation	A transient symptom can motivate investigation of an embolic source even when vision has recovered.
Contralateral weakness and sensory loss, greater in the arm, with aphasia or related language dysfunction	Language-dominant MCA syndrome	Impaired communication can reflect language dysfunction rather than impaired consciousness.
Similar motor findings with neglect, impaired construction, or dressing apraxia	Nondominant MCA syndrome	Awareness of disability and safe participation in care may be impaired.
Leg-predominant contralateral deficits with abulia, sometimes akinetic mutism or incontinence	ACA syndrome	Reduced initiation can be part of the neurological syndrome.
Contralateral motor and sensory deficits with a homonymous visual field deficit	Anterior choroidal syndrome	The combined pattern is more informative than any isolated component; the complete combination is not obligatory.
Ipsilateral facial sensory loss, Horner syndrome, or ataxia with contralateral body pain and temperature loss	Lateral medullary syndrome	Crossed findings support a brainstem localization and make swallowing and airway function relevant to surveillance.
Bilateral motor deficits with abnormal horizontal gaze, potentially a locked-in state	Pontine or basilar syndrome	Profound motor impairment can coexist with preserved awareness.

I would reconstruct the examination as a profile before reducing it to an NIH Stroke Scale (NIHSS) total. Language, attention, gaze, visual fields, limb function, sensation, coordination, and consciousness describe different failures. Repeated documentation makes it possible to distinguish extension of the original deficit from a new syndrome or reduced arousal.

NIHSS is a common language for severity and change. Its weighting also matters: a total can represent different deficits in different hemispheres, and posterior circulation dysfunction may be incompletely represented, as illustrated by Inoa et al., 2014. The management reasoning depends on the actual disability and trajectory.

Reperfusion is an early decision with its own evidence

What the time-to-treatment result measures

The deck gives odds ratios of 2.81 for treatment “under 90 minutes” and 1.55 for 91 to 180 minutes. The time interval requires a correction: the original analysis used 0 to 90 minutes, including 90.

Hacke et al., Lancet 2004 pooled randomized alteplase trials and examined favorable outcome at three months. Its abstract reports rounded estimates:

Onset to treatment	Odds ratio favoring alteplase over placebo	95% confidence interval
0 to 90 minutes	2.8	1.8 to 4.5
91 to 180 minutes	1.6	1.1 to 2.2

The authors reproduce the more precise 2.81 and 1.55 as odds ratios for the global outcome in their ECASS III report, discussion. Thus, the deck’s values agree with that published account; its first interval label is imprecise.

These compare treatment with placebo within time strata. They are not the odds ratio for treating the same patient earlier versus later, an absolute probability of recovery, or a mortality reduction. The diminishing treatment effect explains why an available window does not make delay harmless.

What the 4.5-hour teaching rule leaves unspecified

The deck teaches an IV thrombolysis window under 4.5 hours, followed by checks for an ischemic stroke syndrome, intracranial hemorrhage, extensive established injury, and recent bleeding at a site where hemostasis would be difficult.

ECASS III, Hacke et al., 2008 tested alteplase 3 to 4.5 hours after symptom onset in selected patients. Its exclusions include intracranial hemorrhage, major bleeding risks, and severe infarction involving more than one third of the MCA territory. That supports the historical context of the deck’s checks. Trial exclusions describe the studied population; they are not automatically a present-day contraindication list.

Not traced to the primary source. I did not check the deck’s exact wording about recent bleeding against its cited Korean guideline revision from 2013. Active bleeding, a recent major hemorrhage, and a recent procedure at a noncompressible site are distinct circumstances. The extracted sentence does not supply enough detail to reconstruct an exclusion rule.

The 2026 AHA/ASA acute ischemic stroke guideline supports alteplase or tenecteplase within the usual 4.5-hour window and selected treatment beyond it. It also updates thrombectomy eligibility. The deck’s time limit is therefore incomplete as a description of contemporary reperfusion practice.

My reconstruction is a decision about potential benefit, bleeding risk, disabling deficit, timing, and available treatment capability. Medication exposure, blood pressure, relevant laboratory findings, and prior function also enter the applicable assessment. Completing TOAST classification comes later. IV thrombolysis and thrombectomy are related reperfusion options with distinct eligibility questions.

Classify the mechanism without confusing it with location

TOAST organizes causal hypotheses

The original Adams et al. TOAST paper, Stroke 1993;24:35-41, defines five etiologic categories.

Category	Clinical logic I need to reconstruct
Large-artery atherosclerosis	A relevant atherosclerotic lesion can produce local thrombosis, artery-to-artery embolism, or impaired downstream supply.
Cardioembolism	A cardiac source can generate an embolus capable of explaining the event. Competing arterial causes still matter.
Small-vessel occlusion	A compatible lacunar syndrome and small deep lesion support a penetrating artery mechanism when competing explanations have been assessed.
Other determined etiology	A specific alternative, such as dissection or another vasculopathy, explains the event.
Undetermined etiology	The investigation is incomplete, no cause is found despite evaluation, or competing causes prevent a single assignment.

An MCA syndrome does not select one of these mechanisms. Likewise, atrial fibrillation and an arterial stenosis can coexist. “Undetermined” preserves information about uncertainty and investigation, rather than meaning that the patient has no vascular disease.

Diameter and stenosis thresholds belong to a classification version

The deck describes small-vessel occlusion as a clinically relevant perforator infarct under 20 mm. Original TOAST used a relevant deep or brainstem lesion under 1.5 cm, together with clinical and exclusion criteria. These are different definitions.

The authors’ later Causative Classification System (CCS) description, developed from SSS-TOAST, uses under 20 mm and requires absence of focal parent artery pathology at the perforator origin. Its entry form instead displays 20 mm or less. I have not checked the original Ay 2005 full text against these later web versions. I would retain the recorded diameter and classification version rather than silently resolve that boundary.

For atherothrombosis, the deck lists occlusion, over 50% stenosis, or under 50% with ulceration or thrombosis, in a clinically relevant artery. Original TOAST supports the occlusion or greater-than-50% formulation. The later CCS description uses at least 50%, and explicitly permits lesser stenosis with plaque ulceration or thrombosis, alongside further distribution criteria.

A percentage alone does not establish causation. The lesion must plausibly account for the event, and an occlusion itself does not establish that its cause is atherosclerosis.

The cardiac source list is not an anticoagulation order

The deck attributes its high-risk cardiac sources to Ay et al., Annals of Neurology 2005;58:688-697, the SSS-TOAST classification paper. It lists:

• Left atrial or left ventricular thrombus.
• Atrial fibrillation, including paroxysmal atrial fibrillation; sick sinus syndrome; sustained atrial flutter.
• Recent myocardial infarction within one month.
• Rheumatic mitral or aortic valve disease; bioprosthetic or mechanical valves.
• Chronic myocardial infarction with ejection fraction under 28%.
• Symptomatic congestive heart failure with ejection fraction under 30%.
• Dilated cardiomyopathy and nonbacterial thrombotic endocarditis.

“Rheumatoid” in the deck’s English valve label should be rheumatic. Its mixed Korean and English rhythm labels should not collapse atrial fibrillation and atrial flutter into the same rhythm.

Not traced to the primary source. The original 2005 table is paywalled and I could not read it. The authors’ later CCS form, cardiac evaluation corroborates many entries and places chronic MI with EF under 28% in its high-risk group. However, it places CHF with EF under 30% in the low or uncertain risk group. It also contains additional high-risk sources absent from the deck. I cannot present the deck’s list as a verified, complete transcription of Ay 2005, including its one-month MI boundary.

These are source-classification categories. They do not specify whether anticoagulation is indicated, which agent is appropriate, or when it begins after an infarction.

Each investigation answers a causal question

The deck’s workup becomes easier to reconstruct when organized by purpose:

Question	Investigations named in the deck
Is there relevant arterial disease?	Intracranial and extracranial vascular assessment, carotid studies, selected vessel wall or catheter studies.
Is there a persistent or intermittent rhythm source?	ECG and rhythm monitoring.
Is there a structural cardiac or aortic source?	Transthoracic or transesophageal echocardiography and selected aortic evaluation.
Is there a plausible route for paradoxical embolism?	Evaluation of a patent foramen ovale in the clinical context.
Does the presentation suggest another mechanism?	Selected testing for antiphospholipid antibodies, coagulation disorders, inflammatory disease, or other causes.

This is a menu of hypotheses, not a universal panel. A positive finding can be incidental, and an unperformed investigation cannot be recorded as a negative result. The deck’s DSA expansion is also a transcription error: it means digital subtraction angiography.

Antithrombotic therapy follows mechanism and timing

Platelet adhesion, activation, and aggregation help explain the deck’s antiplatelet branch. Stasis, vessel injury, and hypercoagulability explain its coagulation branch. The “white” and “red” thrombus distinction is a teaching simplification: thrombi contain interacting platelet and fibrin components.

The 2021 AHA/ASA secondary prevention guideline distinguishes antiplatelet treatment for noncardioembolic ischemic stroke from anticoagulation for appropriate cardiac indications such as atrial fibrillation. It reserves short-term dual antiplatelet treatment for defined situations, does not endorse it as routine long-term treatment, and advises against empiric anticoagulation for embolic stroke of undetermined source.

That leaves separate questions about indication, agent, and initiation. A cardiac source does not erase hemorrhagic transformation risk. A prevention strategy is also different from acute clot removal or lysis.

Reconstruct drug targets accurately

Class or agent	Mechanism to retain
Antiplatelet drugs	Interfere with platelet activation or aggregation pathways.
Unfractionated heparin	Enhances antithrombin-mediated inhibition, especially of thrombin and factor Xa. It does not lyse an existing clot.
Warfarin	Inhibits vitamin K recycling through VKORC1, reducing production of functional vitamin K-dependent coagulation proteins.
Dabigatran	Directly inhibits thrombin.
Rivaroxaban, apixaban, edoxaban	Directly inhibit factor Xa.

The corrections to the deck’s heparin and warfarin shorthand follow their official labeling: heparin, warfarin. Warfarin’s mechanism is more precise than “competitive inhibition of vitamin K.”

The deck’s NOACs are commonly called direct oral anticoagulants, or DOACs. Their targets are confirmed in the labels for dabigatran, rivaroxaban, apixaban, and edoxaban. The deck misspells rivaroxaban.

The monitoring concepts also differ: aPTT is associated with unfractionated heparin monitoring, while warfarin uses PT expressed as INR. Routine PT/INR or aPTT results cannot be interpreted as interchangeable measures of DOAC effect. This pharmacology explains classes; it does not provide a prescribing or substitution rule.

A stroke unit makes repeated assessment actionable

The deck defines organized care through trained nursing, cooperation among medical and rehabilitation teams, established procedures, access to urgent investigations, and monitoring of neurological and physiological change. The unit’s function is a continuing cycle of observation, interpretation, and response.

Its general management topics form a connected argument:

• Impaired autoregulation explains concern about abrupt blood pressure reduction. Blood pressure goals depend on the stroke type and treatment context.
• Airway and respiratory dysfunction can threaten oxygen delivery and safe swallowing.
• Dysphagia connects feeding decisions to aspiration, hydration, and nutrition.
• Positioning, skin care, mobility planning, and catheter review address complications of dependence and immobility.
• Rhythm, temperature, glucose, and blood pressure observations help identify systemic contributors to worsening.
• Rehabilitation, cognition, mood, pain, and seizure assessment extend care beyond the initial vascular event.

The deck’s fixed NPO for one to two days is not a rule I can carry forward. Its primary basis is not stated in the deck and I could not trace one. The 2026 AHA/ASA guideline instead describes swallowing screening before oral intake and assessment-based nutritional management. The clinical question is whether intake is safe and adequate.

Check the stroke-unit benefit claim before repeating it

Not traced to the primary source. The deck reports a 14% decrease in one-year mortality and 22% decrease in one-year morbidity, attributed to Brainin et al., Cerebrovascular Diseases 2004;17 Suppl 2:1-14. I verified the bibliographic record, but could not inspect the full paper to verify those numbers, their effect measure, or the endpoint called “morbidity.” They remain deck-reported figures.

The 2020 Stroke Unit Trialists’ Collaboration review independently supports better survival, independence, and residence at home after organized stroke-unit care. It reports specific endpoints, including death, death or institutional care, and death or dependency. That supports the organizational argument without validating the deck’s exact percentages. A relative change, an odds reduction, and a percentage-point difference cannot be substituted for one another.

Deterioration creates a new explanatory problem

END describes a course, not a single mechanism

The correct citation is Thanvi, Treadwell, and Robinson, Postgraduate Medical Journal 2008;84:412-417. The deck spells the first author “Thanbi.”

Not traced to the primary source. The deck places early neurological deterioration (END) within 48 to 72 hours and estimates it in about 20% of patients. I verified the paper and its abstract, but not these numerical claims in its full text or the underlying studies. They remain the deck’s estimates. Frequency depends on the population, observation window, assessment scale, and amount of change counted as deterioration.

The abstract supports associations with initial stroke severity, large-vessel occlusion, diabetes, hypotension, and atrial fibrillation. These are predictors of a worsening course, not explanations of every individual deterioration.

Not traced to the primary source. The deck additionally specifies NIHSS above 7 and hypodensity involving more than 33% of the MCA territory, and lists raised blood pressure, lacunar or noncardiac stroke, total anterior circulation syndrome, elevated urea, a hyperdense MCA sign, and early edema. I could not verify that detailed predictor table against the full review. Its question marks around blood pressure should remain uncertainty, not become a scored rule.

Reconstruct the cause before interpreting a treatment list

The deck’s mechanisms suggest several different routes to worsening:

Candidate explanation	What changes in the clinical reasoning
Collateral failure or systemic circulatory compromise	Worsening may reflect inadequate supply without a new embolus. Physiological changes become explanatory evidence.
Thrombus progression, reocclusion, or recurrent embolism	A new or persistent vascular problem can reopen the reperfusion and prevention questions.
Hemorrhagic transformation	Worsening may represent bleeding, changing the meaning and risk of antithrombotic treatment.
Space-occupying edema	Declining consciousness can reflect a developing mass effect and need for neurosurgical assessment.
Seizure or a postictal deficit	Fluctuation or reduced responsiveness can have an electrical explanation. Antiseizure treatment for an identified seizure addresses a different question from routine prophylaxis.
Systemic illness or metabolic disturbance	Hypoxia, infection, glucose disturbance, or medication effects can contribute to deterioration without extension of the original lesion.

I read reassessment as comparison with the documented baseline: which function changed, when, and alongside which physiological or treatment changes? Repeat investigations then test the competing explanations. An increased NIHSS is evidence of change, not a diagnosis of its cause.

The deck lists recanalization, collateral augmentation, prevention, heparin, and edema management together. These have different indications and evidence. The 2026 AHA/ASA guideline does not support routine acute anticoagulation as a general way to improve stroke outcome, reports no demonstrated functional benefit from studied hemodynamic augmentation approaches, and does not establish benefit from routine antiseizure prophylaxis. The deck’s heparin entry therefore cannot become an automatic response to END.

Malignant MCA infarction changes the immediate objective

“Malignant” describes a course dominated by space-occupying swelling, neurological deterioration, and risk of herniation. In the deck’s sequence, a major hemispheric infarction is followed by edema, displacement, and threatened brainstem function. A successful earlier vascular procedure does not guarantee that swelling will not subsequently matter.

Hacke et al., Archives of Neurology 1996;53:309-315 describes the clinical course of complete MCA territory infarction. It assessed initial presentation with the Scandinavian Stroke Scale and Glasgow Coma Scale. It is historical evidence about this severe phenotype, not a trial validating the deck’s NIHSS cutoffs or contemporary surgical selection.

The prediction criteria have a better-matched original source

The deck’s NIHSS at least 20 for left hemispheric infarction, at least 15 for right, and hypodensity over 50% of the MCA territory correspond to Krieger et al., Stroke 1999;30:287-292.

That study examined the placebo arm of a trial using a case-control design. The NIHSS cutoffs were the minimum baseline scores among patients who died from swelling; comparably severe controls were selected using those cutoffs. Its conclusion concerns patients assessed within six hours who also had nausea or vomiting, or the extensive hypodensity finding.

This is a warning profile derived from a selected sample. The scores were not established as a stand-alone, universally validated prediction rule. Kasner et al., 2001 also found an association between greater-than-50% MCA hypodensity and fatal edema in patients with large hemispheric infarctions.

A better-matched source exists. The deck cites Puetz et al., Lancet Neurology 2007;6:580, a letter about defining a favorable outcome after hemicraniectomy. I verified the identity of that publication, but not support within it for the prediction criteria. Krieger is the directly verified source for the numerical profile.

Pressure control and decompression address different parts of the problem

The deck’s deteriorating consciousness, pupillary, motor, and respiratory patterns illustrate increasing brainstem compromise. I would retain the direction of change, without assuming that herniation always follows a tidy sequence of stages.

The 2021 ESO guideline on space-occupying infarction distinguishes medical rescue from decompressive surgery. It describes short-term mannitol or hypertonic saline as possible rescue measures for raised pressure or impending herniation, while finding insufficient evidence for routine osmotherapy to improve survival or functional outcome. A lower pressure measurement is not itself proof of a better outcome.

Decompression creates space for the swollen brain. Its study logic concerns prevention of fatal compression, with survival and disability considered separately. The same guideline emphasizes evidence for early surgery in selected patients and uncertainty in other groups. I therefore read the deck’s medical-treatment response branch alongside early neurosurgical assessment, rather than as a requirement to wait for advanced herniation.

Discussion of likely dependence, the patient’s values, and acceptable outcomes belongs to this reasoning. The phrase “favorable outcome” requires a definition. The deck’s closing neuroprotection material likewise identifies a research objective; it does not establish a treatment merely because its proposed mechanism is plausible.

Revision checklist

Check	What I should reconstruct without looking
Parallel objectives	Explain how reperfusion, physiological support, etiologic investigation, and recovery overlap in time.
Localization	Recover the distinguishing language, attention, leg-predominant, crossed brainstem, and bilateral pontine patterns.
Severity	Explain why the examination profile and its change matter alongside the NIHSS total.
Time-to-treatment evidence	Identify the comparator, outcome, and correct time intervals in the Hacke pooled analysis.
Eligibility	Separate a teaching window and historical trial exclusions from current treatment guidance.
TOAST	Name the five categories and distinguish absent evidence, incomplete investigation, and competing causes.
Classification versions	Explain why lesion diameter and stenosis boundaries need their source attached.
Cardiac sources	Separate source classification from the indication, agent, and timing of anticoagulation.
Antithrombotic mechanisms	Distinguish platelet inhibition, antithrombin enhancement, vitamin K recycling inhibition, and direct factor inhibition.
Stroke-unit care	Connect repeated assessment, complication prevention, and rehabilitation to the function of the team.
END	Generate vascular, hemorrhagic, swelling, electrical, and systemic explanations for a worsening examination.
Malignant swelling	Explain the origin and limitations of the warning criteria, and separate pressure control, survival, and functional outcome.
Evidence language	Distinguish odds ratios, relative changes, absolute differences, and unspecified “morbidity.”

Why it matters for my work

As a master’s student researching whether medical AI models rely on clinically valid evidence, I need a more specific account of stroke risk than a single vascular-disease label. In my stroke risk prediction project, first stroke, recurrence after stroke, and deterioration during an admission would be different outcomes. This deck does not resolve which population and prediction horizon my project should use.

The mechanism classification gives me hypotheses to examine. Rhythm history can support an embolic-risk argument; relevant atherosclerotic disease supports another pathway. Their coexistence prevents a simple mapping from one feature to one mechanism. I would preserve which investigations established a mechanism and which were missing, rather than treat an administrative subtype as a complete causal explanation.

Treatment variables are particularly difficult. An anticoagulant prescription may identify a high-risk cardiac condition while also changing subsequent risk. Its association with the outcome cannot be read directly as either drug harm or evidence that the model understands embolism. Similarly, rhythm-monitoring orders or stroke-unit admission can encode clinical suspicion and access to care. Their validity as inputs depends on the project’s actual prediction point.

An evidence-reliance audit would therefore distinguish documented clinical antecedents from care-process proxies and examine whether conclusions persist across mechanisms and investigation patterns. Feature attribution alone would not settle this. I still need tests of model reliance whose interventions preserve a clinically coherent patient record.

What I have not resolved

• The full Brainin paper is needed to establish the deck’s mortality and morbidity percentages, endpoints, and effect measures.
• The full Thanvi review is needed for its incidence, time window, and detailed predictor table. The deck’s separate “approximately 19% END” beside edema also lacks a verified denominator or endpoint, so I have not used it as an estimate.
• The original Ay table is needed to reconcile the cardiac source categories and exact numerical boundaries with the later CCS pages. The deck’s recent-bleeding wording and fixed fasting duration also remain unverified against their original teaching sources.
• The extracted infarct-volume graphic lacks enough labels and source information to interpret its outcome relationship. I have not reconstructed a numerical rule from it.
• For my project, I have not established how reliably mechanisms can be adjudicated, whether investigation intensity differs across cohorts, or how to distinguish reliance on clinical risk from reliance on the care pathway.